Heart Health Focused Campaign Set to Kick Off December 1st, 2018
HOUSTON, TX, Nov. 12, 2018 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE – AngioSoma (SOAN), a leading biotechnology research and development company, announces today a new campaign is in production to bring awareness to a range of heart health issues.
AngioSoma is the producer of Liprostin™, a flagship patented pharmaceutical intervention for Peripheral Artery Disease. Currently, 8.5 million people in the United States suffer from this deadly disease and Liprostin™, presently in the approval process of the FDA, is a good alternative treatment for some patients. The awareness campaign will focus on Peripheral Artery Disease, plus other forms of heart disease, with a focus on prevention and early detection.
“The more information people have the earlier heart problems can be identified,” said Alex Blankenship, President of AngioSoma. “Outcomes for patients are much better with early detection and our campaign is focused on this, plus making good lifestyle choices to reduce the risk of developing heart problems.”
The campaign will start December 1, 2018 and will include Facebook, Twitter, and Instagram social channels as well as supporting website content.
You can view and purchase our products on Amazon.com: Go to Amazon Now
Also, products can be found on our ecommerce site: YouthfulBrilliance.com.
ABOUT ANGIOSOMA, INC.
AngioSoma, Inc. (https://www.brandusadesigns.com/partners/angiosoma.com), a Nevada corporation based in Houston, Texas is dedicated to improving the mental and physical wellbeing of men and women. To accomplish that purpose, we are launching a line of supplements under our SomaCeuticals™ common identity. Our supplements cover three industry segments: nutraceuticals, cosmeceuticals, and pharmaceuticals.
NOTICE REGARDING FORWARD LOOKING STATEMENTS
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements.